Phase II clinical trial of 13-cis-retinoic acid and interferon-α-2a in patients with advanced esophageal carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Biomarkers, Tumor
  • Genomic Instability
  • Pancreatic Neoplasms
  • Precision Medicine

abstract

  • This regimen had no significant activity in patients with advanced AC of the esophagus. Further evaluation of IFN plus CRA, using this dose and schedule, is not recommended. In comparison with prior trials of this therapy, a surprising amount of severe nausea and fatigue was observed in this trial.

publication date

  • March 15, 1999

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(19990315)85:6<1213::AID-CNCR1>3.0.CO;2-N

PubMed ID

  • 10189124

Additional Document Info

start page

  • 1213

end page

  • 7

volume

  • 85

number

  • 6